Cargando…

Quantifying lung cancer heterogeneity using novel CT features: a cross-institute study

BACKGROUND: Radiomics-based image metrics are not used in the clinic despite the rapidly growing literature. We selected eight promising radiomic features and validated their value in decoding lung cancer heterogeneity. METHODS: CT images of 236 lung cancer patients were obtained from three differen...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Zixing, Yang, Cuihong, Han, Wei, Sui, Xin, Zheng, Fuling, Xue, Fang, Xu, Xiaoli, Wu, Peng, Chen, Yali, Gu, Wentao, Song, Wei, Jiang, Jingmei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Vienna 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9050978/
https://www.ncbi.nlm.nih.gov/pubmed/35482262
http://dx.doi.org/10.1186/s13244-022-01204-9
_version_ 1784696462670561280
author Wang, Zixing
Yang, Cuihong
Han, Wei
Sui, Xin
Zheng, Fuling
Xue, Fang
Xu, Xiaoli
Wu, Peng
Chen, Yali
Gu, Wentao
Song, Wei
Jiang, Jingmei
author_facet Wang, Zixing
Yang, Cuihong
Han, Wei
Sui, Xin
Zheng, Fuling
Xue, Fang
Xu, Xiaoli
Wu, Peng
Chen, Yali
Gu, Wentao
Song, Wei
Jiang, Jingmei
author_sort Wang, Zixing
collection PubMed
description BACKGROUND: Radiomics-based image metrics are not used in the clinic despite the rapidly growing literature. We selected eight promising radiomic features and validated their value in decoding lung cancer heterogeneity. METHODS: CT images of 236 lung cancer patients were obtained from three different institutes, whereupon radiomic features were extracted according to a standardized procedure. The predictive value for patient long-term prognosis and association with routinely used semantic, genetic (e.g., epidermal growth factor receptor (EGFR)), and histopathological cancer profiles were validated. Feature measurement reproducibility was assessed. RESULTS: All eight selected features were robust across repeat scans (intraclass coefficient range: 0.81–0.99), and were associated with at least one of the cancer profiles: prognostic, semantic, genetic, and histopathological. For instance, “kurtosis” had a high predictive value of early death (AUC at first year: 0.70–0.75 in two independent cohorts), negative association with histopathological grade (Spearman’s r: − 0.30), and altered expression levels regarding EGFR mutation and semantic characteristics (solid intensity, spiculated shape, juxtapleural location, and pleura tag; all p < 0.05). Combined as a radiomic score, the features had a higher area under curve for predicting 5-year survival (train: 0.855, test: 0.780, external validation: 0.760) than routine characteristics (0.733, 0.622, 0.613, respectively), and a better capability in patient death risk stratification (hazard ratio: 5.828, 95% confidence interval: 2.915–11.561) than histopathological staging and grading. CONCLUSIONS: We highlighted the clinical value of radiomic features. Following confirmation, these features may change the way in which we approach CT imaging and improve the individualized care of lung cancer patients.
format Online
Article
Text
id pubmed-9050978
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Vienna
record_format MEDLINE/PubMed
spelling pubmed-90509782022-05-07 Quantifying lung cancer heterogeneity using novel CT features: a cross-institute study Wang, Zixing Yang, Cuihong Han, Wei Sui, Xin Zheng, Fuling Xue, Fang Xu, Xiaoli Wu, Peng Chen, Yali Gu, Wentao Song, Wei Jiang, Jingmei Insights Imaging Original Article BACKGROUND: Radiomics-based image metrics are not used in the clinic despite the rapidly growing literature. We selected eight promising radiomic features and validated their value in decoding lung cancer heterogeneity. METHODS: CT images of 236 lung cancer patients were obtained from three different institutes, whereupon radiomic features were extracted according to a standardized procedure. The predictive value for patient long-term prognosis and association with routinely used semantic, genetic (e.g., epidermal growth factor receptor (EGFR)), and histopathological cancer profiles were validated. Feature measurement reproducibility was assessed. RESULTS: All eight selected features were robust across repeat scans (intraclass coefficient range: 0.81–0.99), and were associated with at least one of the cancer profiles: prognostic, semantic, genetic, and histopathological. For instance, “kurtosis” had a high predictive value of early death (AUC at first year: 0.70–0.75 in two independent cohorts), negative association with histopathological grade (Spearman’s r: − 0.30), and altered expression levels regarding EGFR mutation and semantic characteristics (solid intensity, spiculated shape, juxtapleural location, and pleura tag; all p < 0.05). Combined as a radiomic score, the features had a higher area under curve for predicting 5-year survival (train: 0.855, test: 0.780, external validation: 0.760) than routine characteristics (0.733, 0.622, 0.613, respectively), and a better capability in patient death risk stratification (hazard ratio: 5.828, 95% confidence interval: 2.915–11.561) than histopathological staging and grading. CONCLUSIONS: We highlighted the clinical value of radiomic features. Following confirmation, these features may change the way in which we approach CT imaging and improve the individualized care of lung cancer patients. Springer Vienna 2022-04-28 /pmc/articles/PMC9050978/ /pubmed/35482262 http://dx.doi.org/10.1186/s13244-022-01204-9 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Wang, Zixing
Yang, Cuihong
Han, Wei
Sui, Xin
Zheng, Fuling
Xue, Fang
Xu, Xiaoli
Wu, Peng
Chen, Yali
Gu, Wentao
Song, Wei
Jiang, Jingmei
Quantifying lung cancer heterogeneity using novel CT features: a cross-institute study
title Quantifying lung cancer heterogeneity using novel CT features: a cross-institute study
title_full Quantifying lung cancer heterogeneity using novel CT features: a cross-institute study
title_fullStr Quantifying lung cancer heterogeneity using novel CT features: a cross-institute study
title_full_unstemmed Quantifying lung cancer heterogeneity using novel CT features: a cross-institute study
title_short Quantifying lung cancer heterogeneity using novel CT features: a cross-institute study
title_sort quantifying lung cancer heterogeneity using novel ct features: a cross-institute study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9050978/
https://www.ncbi.nlm.nih.gov/pubmed/35482262
http://dx.doi.org/10.1186/s13244-022-01204-9
work_keys_str_mv AT wangzixing quantifyinglungcancerheterogeneityusingnovelctfeaturesacrossinstitutestudy
AT yangcuihong quantifyinglungcancerheterogeneityusingnovelctfeaturesacrossinstitutestudy
AT hanwei quantifyinglungcancerheterogeneityusingnovelctfeaturesacrossinstitutestudy
AT suixin quantifyinglungcancerheterogeneityusingnovelctfeaturesacrossinstitutestudy
AT zhengfuling quantifyinglungcancerheterogeneityusingnovelctfeaturesacrossinstitutestudy
AT xuefang quantifyinglungcancerheterogeneityusingnovelctfeaturesacrossinstitutestudy
AT xuxiaoli quantifyinglungcancerheterogeneityusingnovelctfeaturesacrossinstitutestudy
AT wupeng quantifyinglungcancerheterogeneityusingnovelctfeaturesacrossinstitutestudy
AT chenyali quantifyinglungcancerheterogeneityusingnovelctfeaturesacrossinstitutestudy
AT guwentao quantifyinglungcancerheterogeneityusingnovelctfeaturesacrossinstitutestudy
AT songwei quantifyinglungcancerheterogeneityusingnovelctfeaturesacrossinstitutestudy
AT jiangjingmei quantifyinglungcancerheterogeneityusingnovelctfeaturesacrossinstitutestudy